Clinical Trials
5 trialsNCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01885195 2021-02-21
SIGNATURE
Pfizer
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT02355431 2019-03-08
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Incyte Corporation
Phase 2 Withdrawn
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed